Breakthrough Device Designation Granted for Roche’s VENTANA TROP2 RxDx Device
Roche's VENTANA TROP2 RxDx Device, a computational companion diagnostic, has received FDA Breakthrough Device Designation.
Roche's VENTANA TROP2 RxDx Device, a computational companion diagnostic, has received FDA Breakthrough Device Designation.
Researchers have developed a novel testing strategy for mesothelioma cancer, focusing on detecting chromosomal rearrangements in cancer DNA.
A new microchip uses exosome analysis to detect lung cancer from a simple blood draw, enhancing speed and sensitivity in cancer diagnostics.
Researchers have developed an AI-powered liquid biopsy to identify lung cancer earlier through DNA fragment patterns in blood.
Read MoreDELFI’s blood-based Lung test has been clinically validated to enhance early detection of lung cancer, demonstrating high sensitivity.
Read MoreOncoHost will highlight the PROphet platform’s capability to predict benefits from therapies across various cancers.
Read MoreOSF HealthCare will use DELFI’s FirstLook Lung blood test to enhance lung cancer screening rates and early detection efforts.
Read MoreCAP developed recommendations for testing immunotherapy biomarkers, such as PD-L1 and TM), in patients with NSCLC.
Read MoreNucleix will present data that demonstrates the potential of a PCR assay to accurately differentiate between small cell lung cancer subtypes.Â
Read MoreThe test guides first-line treatment selection by identifying individuals with the highest likelihood of benefit from PD-1/PD-L1 inhibitors
Read MoreNew noninvasive diagnostic solutions for lung cancer being developed function as a complement to LDCT imaging.
Read MoreThe epigenomic technology platform predicts and monitors immunotherapy responses for patients with non-small cell lung cancer (NSCLC).
Read MoreChromaCode will collaborate with Tennessee Oncology to test the performance of ChromaCode’s HDPCR NSCLC biomarker assay.Â
Read MoreThe diagnostic, which requires only a simple urine test to read the results, could make lung cancer screening more accessible worldwide.
Read MoreFreenome’s PROACT LUNG study is intended to validate the clinical performance of its blood test for lung cancer screening.Â
Read MoreDELFI Diagnostics is supporting the recently introduced Lung Cancer Screening and Prevention Act (H.R. 6693).
Read MoreLiquid biopsies could predict which lung cancer patients are responding to immunotherapies or may develop immune-related side effects.
Read MoreClinical validation data shows that Veracyte’s Percepta Nasal Swab test determines lung cancer risk with high accuracy for certain patients.
Read More